Filter Results
Filter Results
Advanced Synthesis (20) Specialized Modalities (19) Integrated Biologics (17) Capsules & Health Ingredients (5) Corporate (5)
Media Advisory (66) Partnerships (18) New Technologies (16) Sustainability (3) New Products (2) Acquisitions (1) General (1)
2026 (16) 2025 (12) 2024 (21) 2023 (16) 2022 (1)
English (66)
Media AdvisoryX
EnglishX
Reset Filters
   Loading...
Showing 1‐20 of 66
Media Advisory
14 Sep 2026
Lonza Begins Construction of New Pharmaceutical Manufacturing Facility in Bend, Creating More Than 80 Jobs
The new facility will expand Lonza’s US manufacturing footprint and establish its Bend site as a global hub for spray-drying, an advanced manufacturing technology that helps...
Media Advisory
17 Aug 2026
Lonza Launches Rapid Custom Media Prototyping Service to Accelerate Early Bioprocess Development
Rapid access to custom liquid and powder media helps scientists move from formulation design to process decisions faster, while supporting a clearer path to future GMP...
Media Advisory
21 Jul 2026
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC development Collaboration enables...
Media Advisory
02 Jul 2026
Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Technology and Expands Strategic Collaboration
Lonza acquires rights to Nona Biosciences’ blood-brain barrier (BBB) technology, leveraging the brain's iron gateway through a receptor, TfR1, to open new routes for...
Media Advisory
22 Jun 2026
Lonza and InduPro Announce Licensing Agreement to Advance Next-Generation ADC Therapeutics
InduPro to license Lonza’s linker payload technologies and bioconjugation platforms, as InduPro expands its novel ADC therapeutics  Strategic agreement expands access...
Media Advisory
15 Jun 2026
Lonza Grants Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza’s site-specific...
Media Advisory
09 Jun 2026
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
New agreement provides AmMax with access to Lonza’s GlycoConnect®, HydraSpace®, and SYNtecan™ linker-payload technologies Agreement to target development of novel...
Media Advisory
04 Jun 2026
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies
Multi-target agreement positions Stipple Bio to advance next-generation ADC therapies using Lonza’s clinically validated ADC platform Stipple Bio’s Pointillist Platform...
Media Advisory
03 Jun 2026
Lonza Advances Integrated DNA to IND Programs Through Acceleration, De-Risking, and Innovation
Early, integrated insights provide decision‑enabling data that helps to de-risk development and advance progress Accelerated, streamlined DNA‑to‑IND development delivers tox...
Media Advisory
20 May 2026
Lonza and Oxford Nanopore Technologies Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control
Nanopore sequencing combined with machine learning and dedicated workflows simplifies complex QC testing by measuring multiple critical quality attributes in one test Technology...
Media Advisory
12 May 2026
Lonza Expands AAV Offering with Xcite® AAV Stable Producer Cell Line Platform to Industrialize Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and...
Media Advisory
07 May 2026
Bristol Myers Squibb Licenses Antibody-Drug Conjugate Technology from Lonza
Agreement grants Bristol Myers Squibb (BMS) access to the SYNtecan™ linker-payload platform, along with GlycoConnect® and HydraSpace® technologies Basel, Switzerland, and...
Media Advisory
31 Mar 2026
Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into Late-Stage Clinical Development
Lonza collaborates with a biotech innovator to advance a promising oncology drug candidate, bimiralisib cGMP manufacturing to be provided at Lonza’s Highly Potent Active...
Media Advisory
30 Mar 2026
ImmuneOncia Therapeutics and Lonza Collaborate to Manufacture Danburstotug, a PD-L1 Antibody Targeting Immuno-Oncology
Lonza to support development and manufacturing of ImmuneOncia’s Danburstotug with a complete and integrated end-to-end drug substance and drug product solution Collaboration to...
Media Advisory
26 Mar 2026
Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimization
New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and...
Media Advisory
19 Feb 2026
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development
Lonza strengthens its integrated Advanced Synthesis offering with industry-leading early-phase bioconjugates development capabilities and payload and linker technologies The...
Media Advisory
11 Dec 2025
Lonza’s Cocoon® Platform Receives Advanced Manufacturing Technologies (AMT) Designation from the U.S. FDA
FDA granted Lonza’s Cocoon® Platform the Advanced Manufacturing Technologies (AMT) Designation  Designation expected to reduce regulatory uncertainty and promote adoption...
Media Advisory
27 Oct 2025
Lonza to Expand Bioscience Testing Offering With the Acquisition of Redberry
Lonza to acquire Redberry SAS, an innovative company specializing in rapid microbiology testing solutions Acquisition to include Red One™ solid-phase cytometry platform for...
Media Advisory
08 Oct 2025
Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH)
New aseptic state-of-the-art filling line in Stein (CH) designed for biologics and highly potent products, such as antibody-drug conjugates (ADCs), has received Swissmedic...
Media Advisory
06 Oct 2025
Lonza Expands its TheraPEAK® Product Portfolio with the Addition of AmpliCell® Cytokine Range and TheraPEAK® 293-GT® Medium
AmpliCell® Cytokines enable cell expansion optimization, batch-to-batch consistency and easy transition from research to manufacturing TheraPEAK® 293-GT® Medium System aims to...